[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100630292":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":32,"locations":42,"responsibleParty":64,"collaborators":66,"id":69,"slug":70,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":71,"sex":77,"minAge":78,"maxAge":79,"enrollmentInfo":80,"targetDuration":31,"studyType":83,"phases":84,"briefSummary":86,"conditions":87,"keywords":89,"overallStatus":93,"whyStopped":31,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},{"fullName":5,"class":6},"Foundation University Islamabad","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Kligman's regimen","ACTIVE_COMPARATOR","Nightly Kligman's regimen for 8 weeks with mineral sunscreen.",[13],"Drug: Kligman's Regimen",{"label":15,"type":16,"description":17,"interventionNames":18},"Topical 30% Metformin","EXPERIMENTAL","Participants will apply topical 30% metformin cream once nightly on affected facial areas for 8 weeks, with concurrent use of mineral sunscreen.",[19],"Drug: Topical 30% metformin cream",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Topical 30% metformin cream","Participants will be randomized to one of two topical drug regimens applied once nightly for 8 weeks. Both groups will also use mineral sunscreen available from the hospital pharmacy.",[15],[27],"kligman regimen",{"type":22,"name":29,"description":11,"armGroupLabels":30,"otherNames":31},"Kligman's Regimen",[9],null,[33,38],{"name":34,"role":35,"phone":36,"phoneExt":31,"email":37},"Dr. Lyba Khan, FCPS, Fellowship in Derma","CONTACT","+923334400850","lybakhan95@gmail.com",{"name":39,"role":35,"phone":40,"phoneExt":31,"email":41},"Dr. Arfan ul Bari, FCPS Derma","+923016547007","albariul@gmail.com",[43],{"facility":44,"status":31,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"Fauji Foundation Hospital, Rawalpindi","Rawalpindi","Punjab Province","44000","Pakistan","PK",{"type":51,"coordinates":52},"Point",[53,54],73.0479,33.59733,{"lat":54,"lon":53},[57,61],{"name":58,"role":35,"phone":59,"phoneExt":31,"email":60},"Ayesha Saeed, PhD","03325756579","ayeshasaeed@fui.edu.pk",{"name":62,"role":63,"phone":31,"phoneExt":31,"email":31},"Dr. Lyba Khan, FCPS","PRINCIPAL_INVESTIGATOR",{"type":65,"investigatorFullName":31,"investigatorTitle":31,"investigatorAffiliation":31,"oldNameTitle":31,"oldOrganization":31},"SPONSOR",[67],{"name":68,"class":6},"Fauji Foundation Hospital","100630292","comparative-evaluation-of-topical-30-metformin-and-kligmans-regimen-in-women-with-melasma-100630292",false,"NCT07485777","Comparative Evaluation of Topical 30% Metformin and Kligman's Regimen in Women With Melasma","A Novel Approach to Melasma Management: Comparative Evaluation of Topical 30% Metformin and Kligman's Regimen in Middle-Aged Women","Melasma","Inclusion Criteria:\n\n* Female patients aged 35-55 years\n* Clinically diagnosed epidermal or dermal melasma (confirmed by Wood's lamp examination)\n* Fitzpatrick skin types III-V\n* Duration of melasma ≥6 months\n* No topical or systemic treatment for melasma in the past month\n\nExclusion Criteria:\n\n* Pregnancy or lactation\n* Known allergy to study medications\n* Active facial dermatitis, acne, or recent cosmetic procedures","FEMALE","35 Years","55 Years",{"count":81,"type":82},82,"ESTIMATED","INTERVENTIONAL",[85],"NA","It's a prospective, randomised, assessor-blinded clinical study comparing topical 30% metformin with Kligman's regimen for melasma in women aged 35-55 years at Fauji Foundation Hospital, Rawalpindi. The study seeks to ascertain which treatment yields a more significant decrease in the modified MASI score over an 8-week period and which treatment is associated with fewer adverse effects, such as erythema, burning, peeling, and post-inflammatory hyperpigmentation. A total of 82 participants will be enrolled and randomly assigned to either metformin cream or Kligman's regimen, with both groups also using sunscreen. Assessments will be done at baseline, week 4, and week 8 through mMASI scoring, photographs, and side-effect monitoring. Data will be analyzed in SPSS 26 using t-tests and chi-square testing. The study is based on evidence suggesting metformin may offer comparable efficacy with better tolerability.",[88,75],"Melasma (Facial Melasma)",[75,90,27,91,92],"topical metformin","hyper-pigmentation","mMASI","NOT_YET_RECRUITING","2026-03-17",{"date":96,"type":97},"2026-03-20","ACTUAL",{"date":99,"type":82},"2026-07-01",{"date":101,"type":82},"2027-06-01",{"name":5,"class":6},1]